Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including mRNA, siRNA, replicon RNA, asRNA, DNA, and gene editing therapeutics.
SAN DIEGO, March 06, 2025--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company focused on the development ...
ARCT stock opened at $14.55 on Friday. Arcturus Therapeutics has a 52-week low of $14.11 and a 52-week high of $45.00. The business has a fifty day moving average of $16.95 and a two-hundred day ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback